Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Benitec Biopharma’s DNA-directed RNA interference platform can generate single-application therapies to silence defective genes in a wide range of diseases whilst overcoming many of the limitations of short interfering RNA.
Vaccinex’s proprietary full-length human antibody discovery engine, ActivMAb, integrates selection and manufacturing in the same mammalian host to streamline development.
The French Institute of Health and Medical Research (Inserm) has developed a unique model for technology transfer through Inserm Transfert, its subsidiary in charge of de-risking innovative preclinical projects and bridging discovery and clinical research.
Histide’s Cell Recoding Molecules provide a diverse source of nonmutagenic extracellular therapeutic agents for tissue regeneration and disease healing.
Probiodrug’s novel approach targets a modified form of β-amyloid, which has a key role in the creation of toxic Aβ oligomers. The company’s lead product is a first-in-class oral small-molecule glutaminyl cyclase inhibitor.
Valuations and volume are up in a buoyant year for biopharmaceutical dealmaking. From tax inversions to gene therapy and, of course, immuno-oncology, 2014 and early 2015 featured plenty of wheeling and dealing.
Today, academic-industrial partnerships are part of an integrated development strategy for any of the world’s top ten pharmaceutical companies and a growing number of academic institutions.
Regenerative medicine and advanced technologies make up a diverse group of therapeutics. As curative strategies for treating disease, they have the potential to alter the standard of care for many indications. With associated risks now tempered, investors and big pharma are showing interest.
Next-generation sequencing platforms are building market share not only in the research setting but also increasingly in population research and clinical applications.
Venture capital investment in devices remains lackluster, but megamergers and startups in digital health, drug delivery and minimally invasive technology are providing new impetus to today’s evolving medical technology industry.
After a period of setbacks and the exodus of high-profile companies from neuroscience research and development, industry leaders predict a rebound in neuroscience investment and deal activity in areas such as pain.
Big pharma’s interest in the therapeutic potential of modulating the body’s own bacterial ecosystem is growing, particularly with regard to the treatment of inflammatory disorders.
Although specific age-related disorders such as Alzheimer’s disease continue to be a focus of research and development investment and dealmaking activity, companies are also beginning to approach aging in a broader way.